Lysogene Announces the Conversion of the Reorganization Proc

Regulatory News: Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that the Commercial Court of Nanterre has decided to

Related Keywords

France , La Tour Du Pin , Rhôalpes , French , Gewinn Nur , Euronext , Weizmann Institute Of Science , Regulatory News , Commercial Court , Weizmann Institute , French Autorit , Des March , French Markets Authorities , Financial Officer , Lysogene , Nnounces , Conversion , Reorganization , Proceedings , Judicial , Liquidation , Elisting ,